Schedule 13G ownership disclosure

Karyopharm Therapeutics Inc

Common Stock, no par value · CUSIP: 48576U205

Event date: 2025-10-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Opaleye Management Inc.

    Shares: 1,569,002.00 · Class: 9.48%

  • Opaleye, L.P.

    Shares: 1,569,002.00 · Class: 9.48%

  • James Silverman

    Shares: 1,569,002.00 · Class: 9.48%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001493152-25-018449
Form type
SCHEDULE 13G
Filer
Karyopharm Therapeutics Inc.
CIK
CIK 1503802
Filed
Oct 17, 2025
Reporting period
Oct 10, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub